
Issuer & Securities

Issuer/ Manager

HYPHENS PHARMA INTERNATIONAL LIMITED

Securities

HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5

GENERAL ANNOUNCEMENT::CHANGE IN COMPOSITION OF THE BOARD OF DIRECTORS AND BOARD COMMITTEES

Announcement Details

Announcement Title

General Announcement

Date & Time of Broadcast

17-Apr-2020 17:55:06

Status

New

Announcement Sub Title

CHANGE IN COMPOSITION OF THE BOARD OF DIRECTORS AND BOARD COMMITTEES

Announcement Reference

SG200417OTHRJC07

Submitted By (Co./ Ind. Name)

Lim See Wah

Designation

Executive Chairman & CEO

Description (Please provide a detailed description of the event in the box below)

Please refer to the attached.

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor, DBS Bank Ltd. ("Sponsor") for compliance with the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact persons for the Sponsor are Ms Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Senior Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.

Attachments

[HPIL%20-%20Annt Change%20in%20board%20composition 170420.pdf](#)

Total size = 138K MB

CHANGE IN COMPOSITION OF THE BOARD OF DIRECTORS AND BOARD COMMITTEES

The Board of Directors of Hyphens Pharma International Limited (the “**Company**”) wishes to announce the following changes in the composition of the Board and Board Committees of the Company:

- a) Dr Poon Thong Yuen (“**Dr Poon**”) has tendered his resignation as Independent Director of the Company with effect from 8 May 2020; and he will concurrently relinquish his position as Chairman of the Nominating Committee and as a member of the Audit Committee and Remuneration Committee of the Company.

The Board would like to express its gratitude to Dr Poon for his valuable contributions to the Company during his tenure.

- b) Ms Tan Seok Hoong @Mrs Audrey Liow would assume the position of Chairman of the Nominating Committee and member of the Audit Committee of the Company, with effect from 8 May 2020.

Consequential to the above changes, the composition of the Board and Board Committees of the Company with effect from 8 May 2020 shall be as follows:

Board of Directors

Mr Lim See Wah	(Executive Chairman & CEO)
Mr Tan Chwee Choon	(Executive Director)
Dr Tan Kia King	(Non-Executive Director)
Mr Heng Wee Koon	(Lead Independent Director)
Mr Ng Eng Leng	(Independent Director)
Ms Tan Seok Hoong @Mrs Audrey Liow	(Independent Director)

Audit Committee

Mr Heng Wee Koon	(Chairman)
Mr Ng Eng Leng	(Member)
Ms Tan Seok Hoong @Mrs Audrey Liow	(Member)

Nominating Committee

Ms Tan Seok Hoong @Mrs Audrey Liow	(Chairman)
Mr Heng Wee Koon	(Member)
Dr Tan Kia King	(Member)

Remuneration Committee

Mr Ng Eng Leng	(Chairman)
Mr Heng Wee Koon	(Member)

HYPHENS PHARMA INTERNATIONAL LIMITED

Registration No. 201735688C

(Incorporated in Singapore)

The Company is in the midst of looking for an additional Independent Director who is expected to fill the vacancy in the Remuneration Committee in compliance with the SGX-ST Listing Manual Section B: Rules of Catalist and the recommendation under the Code of Corporate Governance.

The detailed announcement pursuant to Rule 704(6) of Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited in relation to the resignation of Dr Poon will be released separately via SGXNET.

BY ORDER OF THE BOARD

Lim See Wah

Executive Chairman and Chief Executive Officer

Date: 17 April 2020

*This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor, DBS Bank Ltd. ("**Sponsor**") for compliance with the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact persons for the Sponsor are Ms Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Senior Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.